JP2005082523A5 - - Google Patents

Download PDF

Info

Publication number
JP2005082523A5
JP2005082523A5 JP2003315087A JP2003315087A JP2005082523A5 JP 2005082523 A5 JP2005082523 A5 JP 2005082523A5 JP 2003315087 A JP2003315087 A JP 2003315087A JP 2003315087 A JP2003315087 A JP 2003315087A JP 2005082523 A5 JP2005082523 A5 JP 2005082523A5
Authority
JP
Japan
Prior art keywords
homocysteic acid
homocysteine
disease
metabolism
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003315087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005082523A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2003315087A priority Critical patent/JP2005082523A/ja
Priority claimed from JP2003315087A external-priority patent/JP2005082523A/ja
Publication of JP2005082523A publication Critical patent/JP2005082523A/ja
Publication of JP2005082523A5 publication Critical patent/JP2005082523A5/ja
Pending legal-status Critical Current

Links

JP2003315087A 2003-09-08 2003-09-08 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬 Pending JP2005082523A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003315087A JP2005082523A (ja) 2003-09-08 2003-09-08 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003315087A JP2005082523A (ja) 2003-09-08 2003-09-08 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬

Publications (2)

Publication Number Publication Date
JP2005082523A JP2005082523A (ja) 2005-03-31
JP2005082523A5 true JP2005082523A5 (enExample) 2006-11-09

Family

ID=34415455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003315087A Pending JP2005082523A (ja) 2003-09-08 2003-09-08 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬

Country Status (1)

Country Link
JP (1) JP2005082523A (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007230912A (ja) * 2006-03-01 2007-09-13 Mitsubishi Gas Chem Co Inc 神経再生促進剤、および該促進剤を含む機能性食品
JP2007269769A (ja) * 2006-03-10 2007-10-18 Ultizyme International Ltd 神経変性疾患関連蛋白質凝集線維化抑制剤
WO2007116458A1 (ja) * 2006-03-30 2007-10-18 Tohru Hasegawa 神経変性疾患治療薬
EP2011498A4 (en) * 2006-04-10 2009-11-11 Mitsubishi Gas Chemical Co AGENT FOR IMPROVING THE BRAIN FUNCTIONS AND FUNCTIONAL FOOD CONTAINING THE IMPROVING AGENT
WO2009078445A1 (ja) * 2007-12-17 2009-06-25 Alfresa Pharma Corporation 医薬品
JP2012158527A (ja) * 2011-01-31 2012-08-23 Mitsubishi Gas Chemical Co Inc うつ予防
JPWO2015060317A1 (ja) * 2013-10-22 2017-04-06 長谷川　亨 神経変性疾患の検査方法
JP2017175966A (ja) * 2016-03-29 2017-10-05 三菱瓦斯化学株式会社 ピロロキノリンキノン含有紅茶風飲料
JP7332489B2 (ja) * 2019-01-28 2023-08-23 サントリーホールディングス株式会社 ホスホジエステラーゼ３阻害用組成物及び血小板凝集抑制用組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02196720A (ja) * 1989-01-12 1990-08-03 Fuji Kagaku Kogyo Kk 脳疾患用剤
JPH06211660A (ja) * 1992-02-07 1994-08-02 Sagami Chem Res Center 神経成長因子産生促進剤
GB9916536D0 (en) * 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
EP1246632A4 (en) * 1999-12-30 2004-08-18 Proteotech Inc CATECHINE AND GREEN TEA EXTRACT FOR TREATING AMYLOIDOSES IN GENERAL OR. AT ALZHEIMER
JP2004231585A (ja) * 2002-12-05 2004-08-19 Fancl Corp 生体内ホモシステインレベル低減用および上昇抑制用組成物

Similar Documents

Publication Publication Date Title
US11207279B2 (en) Application of R-ketamine and salt thereof as pharmaceuticals
Grant Dietary links to Alzheimer's disease: 1999 update
Jaroonwitchawan et al. Curcumin attenuates paraquat-induced cell death in human neuroblastoma cells through modulating oxidative stress and autophagy
US20090143433A1 (en) Cocktail for modulation of alzheimer's disease
US10821130B2 (en) Omega 3 fatty acids, no releasing compound and vitamin B12 as neuroprotectant in patients with no dementia
Musa et al. Preventive activity of ascorbic acid on lead acetate induced cerebellar damaged in adult Wistar rats
JP2019518034A (ja) 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用
EP3638278B1 (en) Neuroprotective compositions and their use
JP2005082523A (ja) 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬
EP3028704B1 (en) Combinations of methotrexate and simvastatin for use in the treatment of osteosarcoma
Theodosis-Nobelos et al. Efforts towards repurposing of antioxidant drugs and active compounds for multiple sclerosis control
US20250134892A1 (en) Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine
US7645795B2 (en) Method for treating amyotrophic lateral sclerosis
Pinton et al. p, p′-Methoxyl-diphenyl diselenide prevents neurodegeneration and glial cell activation induced by streptozotocin in rats
US20140044690A1 (en) High-Energy Compounds for Use in Alzheimer's and Other Neurodegenerative Diseases
US20210220322A1 (en) Disease Modifying Methods For Treating Neurodegenerative Diseases Using Nootropic Agents
Tanideh et al. Effects of Pentoxifylline in a rat model of Manganism: Evaluation of the possible toxicity
US9192641B2 (en) Health supplement using guarana extract
Salavoura Metals and Disease
Länger Assessment report on Rhodiola rosea L., rhizoma et radix
IT201800002947A1 (it) Associazione per uso, come coadiuvante, per il miglioramento della qualità di vita in soggetti con disturbi del movimento
Antal et al. Alzheimer’s Disease: An epidemiologic disaster from nutritional perspective
US20180078602A1 (en) Methods and compositions for extending the efficacy of phosphodiesterase inhibitors for treating erectile dysfunction, and compositions for inhibiting the onset and slowing the progression of erectile dysfunction
Grover et al. Aluminium Exposure Routes, Absorption, and Excretion Mechanism
JP4896531B2 (ja) 血中ＣｏＱ１０量を増加させる医薬組成物